Tianjin Pharma Da Ren Tang Group (SGX:T14, SHA:600329) closed the acquisition of a 15% equity interest in Tianjin Pharmaceutical Group Finance, a filing with the Singapore Exchange said on Monday.
The dual-listed pharmaceutical company was notified of a registration notice by the administration of market regulation of China for the transfer of the 15% equity interest in Tianjin Pharmaceutical Group Finance held by Lisheng Pharma.
Following the completion of the proposed acquisition, the company's shareholding in Tianjin Pharmaceutical Group Finance has increased to 30%.
Price (SGD): S$2.20, Change: S$-0.01, Percent Change: -0.45%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments